Clinical Trial: Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968806) titled 'Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection' on March 31.

Brief Summary: This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly [IM] preoperatively and 30 mg twice daily [BID] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be...